Belite Bio Ownership
| BLTE Stock | USD 63.26 4.18 6.20% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Belite |
Belite Stock Ownership Analysis
About 59.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.1. Belite Bio ADR had not issued any dividends in recent years. Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. For more info on Belite Bio ADR please contact YuHsin MBA at 858 246 6240 or go to https://www.belitebio.com.Besides selling stocks to institutional investors, Belite Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Belite Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Belite Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Belite Bio Quarterly Liabilities And Stockholders Equity |
|
About 59.0% of Belite Bio ADR are currently held by insiders. Unlike Belite Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Belite Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Belite Bio's insider trades
Belite Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Belite Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Belite Bio ADR backward and forwards among themselves. Belite Bio's institutional investor refers to the entity that pools money to purchase Belite Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Jpmorgan Chase & Co | 2024-06-30 | 88.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 8.0 | Marshall Wace Asset Management Ltd | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-09-30 | 0.0 | State Street Corp | 2024-06-30 | 15.7 K | Geode Capital Management, Llc | 2024-09-30 | 6.7 K | Citadel Advisors Llc | 2024-09-30 | 6.5 K | Hrt Financial Llc | 2024-06-30 | 5.4 K | Xtx Topco Ltd | 2024-09-30 | 5.4 K | Point72 Asset Management, L.p. | 2024-09-30 | 4.8 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.1 K |
Belite Bio Outstanding Bonds
Belite Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Belite Bio ADR uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Belite bonds can be classified according to their maturity, which is the date when Belite Bio ADR has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| BCECN 365 15 AUG 52 Corp BondUS0778FPAJ86 | View | |
| BCECN 32 15 FEB 52 Corp BondUS0778FPAH21 | View | |
| BCECN 215 15 FEB 32 Corp BondUS0778FPAG48 | View | |
| BCECN 365 17 MAR 51 Corp BondUS0778FPAF64 | View | |
| BELL CDA 4464 Corp BondUS0778FPAA77 | View |
Belite Bio Corporate Filings
6K | 4th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 1st of October 2024 Other Reports | ViewVerify | |
| 29th of April 2024 Other Reports | ViewVerify | |
13A | 12th of February 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Belite Bio ADR is a strong investment it is important to analyze Belite Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Belite Bio's future performance. For an informed investment choice regarding Belite Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Belite Bio ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Belite Bio. If investors know Belite will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Belite Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Return On Assets (0.26) | Return On Equity (0.40) |
The market value of Belite Bio ADR is measured differently than its book value, which is the value of Belite that is recorded on the company's balance sheet. Investors also form their own opinion of Belite Bio's value that differs from its market value or its book value, called intrinsic value, which is Belite Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Belite Bio's market value can be influenced by many factors that don't directly affect Belite Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Belite Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Belite Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Belite Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.